Hoth Therapeutics, Inc.
HOTH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3 | $3 | $5 | $8 |
| G&A Expenses | $5 | $4 | $6 | $7 |
| SG&A Expenses | $5 | $4 | $6 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $8 | $11 | $14 |
| Operating Income | -$8 | -$8 | -$11 | -$14 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$8 | -$8 | -$11 | -$14 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$8 | -$11 | -$14 |
| % Margin | – | – | – | – |
| EPS | -1.28 | -2.3 | -9.5 | -16.03 |
| % Growth | 44.3% | 75.8% | 40.7% | – |
| EPS Diluted | -1.28 | -2.3 | -9.5 | -16.03 |
| Weighted Avg Shares Out | 6 | 3 | 1 | 1 |
| Weighted Avg Shares Out Dil | 6 | 3 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $8 | $8 | $11 | $0 |
| EBITDA | $0 | -$0 | $0 | -$14 |
| % Margin | – | – | – | – |